Ginkgo Bioworks Holdings (DNA) Non-Current Assets (2020 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Non-Current Assets came in at $623.1 million in Q1 2026, down 14.52% YoY from $728.9 million in Q1 2025, and down 3.82% on a QoQ basis from $647.9 million in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Non-Current Assets (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 7 years of Non-Current Assets data on file, last reported at $623.1 million in Q1 2026.
- Quarterly Non-Current Assets fell 14.52% year-over-year to $623.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 billion (down 15.86% YoY) and the FY2025 annual result came in at $647.9 million, down 16.37% from the prior year.
- Non-Current Assets fell to $623.1 million in Q1 2026, from $647.9 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $1.1 billion in Q1 2023 to a low of $351.9 million in Q1 2022.
- A 5-year average of $732.7 million and a median of $708.0 million in 2025 frame the typical range for Non-Current Assets.
- The widest YoY moves for Non-Current Assets: up 213.05% in 2022, down 79.6% in 2022.
- Tracing DNA's Non-Current Assets over 5 years: stood at $1.1 billion in 2022, then plunged by 39.08% to $663.6 million in 2023, then grew by 16.74% to $774.7 million in 2024, then slipped by 16.37% to $647.9 million in 2025, then slipped by 3.82% to $623.1 million in 2026.
- The last three Non-Current Assets figures came in at $623.1 million (Q1 2026), $647.9 million (Q4 2025), and $683.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn | 657.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 657.51 Mn |
| Mar 31, 2026 | 623.12 Mn |
| Dec 31, 2025 | 647.86 Mn |
| Sep 30, 2025 | 683.08 Mn |
| Jun 30, 2025 | 707.98 Mn |
| Mar 31, 2025 | 728.93 Mn |
| Dec 31, 2024 | 774.71 Mn |
| Sep 30, 2024 | 818.40 Mn |
| Jun 30, 2024 | 841.89 Mn |
| Mar 31, 2024 | 678.74 Mn |
| Dec 31, 2023 | 663.59 Mn |
| Sep 30, 2023 | 884.55 Mn |
| Jun 30, 2023 | 1.07 Bn |
| Mar 31, 2023 | 1.09 Bn |
| Dec 31, 2022 | 1.09 Bn |
| Sep 30, 2022 | 408.69 Mn |
| Jun 30, 2022 | 395.37 Mn |
| Mar 31, 2022 | 351.89 Mn |
| Dec 31, 2021 | 347.95 Mn |
| Sep 30, 2021 | 340.02 Mn |